Virax Biolabs Group Limited (VRAX) Stock Ticker
Market factors today
Unlock the full VRAX picture
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
VRAX stock facts
| Ticker symbol | VRAX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $431,925 |
| CEO | James Foster |
| Employees | 26 |
| Headquarters | Lanarkshire, SC, GB |
| IPO date | 2022-07-21 |
| Website | viraxbiolabs.com |
What you can see for VRAX on Tickr
Live VRAX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VRAX report.
Rankings
FAQ
What is the ticker symbol for Virax Biolabs Group Limited?
The ticker symbol for Virax Biolabs Group Limited is VRAX, listed on the NASDAQ.
What is VRAX?
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.